ROMANIAN EXPERIENCE WITH MANAGED ENTRY AGREEMENTS FOR DRUGS

被引：0
|
作者：
Radu, P. [1 ]
Stoica, I [1 ]
Udroiu, P. [1 ]
机构：
[1] Roche Romania SRL, Bucharest, Romania
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.1247
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP353
引用
收藏
页码：S210 / S211
页数：3
相关论文
共 50 条
  • [41] IMPLEMENTING MANAGED ENTRY AGREEMENTS IN PRACTICE: THE DUTCH REALITY CHECK
    Makady, A.
    van Veelen, A.
    de Boer, A.
    Hillege, J. L.
    Klungel, O.
    Goettsch, W.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A702 - A702
  • [42] Managed Entry Agreements for Pharmaceuticals in the Context of Adaptive Pathways in Europe
    Bouvy, Jacoline C.
    Sapede, Claudine
    Garner, Sarah
    [J]. FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [43] The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications
    Ferrario, Alessandra
    Araja, Diana
    Bochenek, Tomasz
    Catic, Tarik
    Danko, David
    Dimitrova, Maria
    Furst, Jurij
    Greiciute-Kuprijanov, Ieva
    Hoxha, Iris
    Jakupi, Arianit
    Laidmae, Erki
    Loblova, Olga
    Mardare, Ileana
    Markovic-Pekovic, Vanda
    Meshkov, Dmitry
    Novakovic, Tanja
    Petrova, Guenka
    Pomorski, Maciej
    Tomek, Dominik
    Voncina, Luka
    Haycox, Alan
    Kanavos, Panos
    Bonanno, Patricia Vella
    Godman, Brian
    [J]. PHARMACOECONOMICS, 2017, 35 (12) : 1271 - 1285
  • [44] THE USE OF MANAGED ENTRY AGREEMENTS FOR ADVANCED THERAPIES IN EU5
    Hanna, E.
    Marre, C.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S789 - S789
  • [45] TOWARDS THE DEVELOPMENT OF MANAGED ENTRY AGREEMENTS GUIDELINES FOR HEALTH TECHNOLOGIES IN BRAZIL
    Guerra-Junior, A. A.
    Dias, C.
    Godman, B.
    Ferrario, A.
    Azevedo, P.
    Peres Gargano, L.
    de Figueiredo Zuppo, I
    Lessa Pantuzza, L.
    Barbosa de Morais Alves, C.
    Macedo do Nascimento, R. C.
    Lovato Pires de Lemos, L.
    Ribeiro, N.
    Iunes, R.
    Pippo, T.
    Curi Hauegen, R.
    Vassalo, C.
    Delgadillo, J.
    Roig, M.
    Kwon, H. Y.
    Pwu, J.
    Gambogi, R.
    Hernandez, C.
    Canuto Santos, V. C.
    Vianna, D.
    Acurcio, F. A.
    Alvares, J.
    [J]. VALUE IN HEALTH, 2020, 23 : S295 - S295
  • [46] THE USE OF MANAGED ENTRY AGREEMENTS (MEAS) FOR ACCESSING INNOVATIVE HEALTH TECHNOLOGIES
    Kodjamanova, P.
    Bennetts, L.
    Bellaoui, Y.
    Ciritel, A.
    Bagnall, R.
    Atanasov, P.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S290 - S290
  • [47] The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications
    Alessandra Ferrario
    Diāna Arāja
    Tomasz Bochenek
    Tarik Čatić
    Dávid Dankó
    Maria Dimitrova
    Jurij Fürst
    Ieva Greičiūtė-Kuprijanov
    Iris Hoxha
    Arianit Jakupi
    Erki Laidmäe
    Olga Löblová
    Ileana Mardare
    Vanda Markovic-Pekovic
    Dmitry Meshkov
    Tanja Novakovic
    Guenka Petrova
    Maciej Pomorski
    Dominik Tomek
    Luka Voncina
    Alan Haycox
    Panos Kanavos
    Patricia Vella Bonanno
    Brian Godman
    [J]. PharmacoEconomics, 2017, 35 : 1271 - 1285
  • [48] Managed Entry Agreements: Learnings for Design and Implementation in Light of International Experiences
    Paredes Fernandez, Daniela Maria
    Lenz Alcayaga, Rony Christian
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2019, 20 : 51 - 59
  • [49] Stakeholder views of managed entry agreements: A literature review of national studies
    Thanimalai, Subramaniam
    Choon, Wai Yee
    Lee, Kenneth Kwing-Chin
    [J]. HEALTH POLICY OPEN, 2021, 2
  • [50] How Do Iranian Stakeholders Think About Pharmaceutical Managed Entry Agreements?
    Shobeiri, Nikta
    Peiravian, Farzad
    Yousefi, Nazila
    [J]. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2022, 21 (01):
12345